anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Corneal neovascularization (CoNV) threatens vision by disrupting corneal avascularity, however, current treatments, including pharmacotherapy and surgery, are hindered by limitations in efficacy and adverse effects. Minocycline, known for its anti-inflammatory properties, could suppress CoNV but faces challenges in effective delivery due to the cornea's unique structure. Therefore, in this study a novel drug delivery system using minocycline-loaded nano-hydroxyapatite/poly (lactic-co-glycolic acid) (nHAP/PLGA) nanoparticles was developed to improve treatment outcomes for CoNV.
RESULTS: Ultra-small nHAP was synthesized using high gravity technology, then encapsulated in PLGA by a double emulsion method to form nHAP/PLGA microspheres, attenuating the acidic by-products of PLGA degradation. The MINO@PLGA nanocomplex, featuring sustained release and permeation properties, demonstrated an efficient delivery system for minocycline that significantly inhibited the CoNV area in an alkali-burn model without exhibiting apparent cytotoxicity. On day 14, the in vivo microscope examination and ex vivo CD31 staining corroborated the inhibition of neovascularization, with the significantly smaller CoNV area (29.40% ± 6.55%) in the MINO@PLGA Tid group (three times daily) than that of the control group (86.81% ± 15.71%), the MINO group (72.42% ± 30.15%), and the PLGA group (86.87% ± 14.94%) (p < 0.05). Fluorescein sodium staining show MINO@PLGA treatments, administered once daily (Qd) and three times daily (Tid) demonstrated rapid corneal epithelial healing while the Alkali injury group and the DEX group showed longer healing times (p < 0.05). Additionally, compared to the control group, treatments with dexamethasone, MINO, and MINO@PLGA were associated with an increased expression of TGF-β as evidenced by immunofluorescence, while the levels of pro-inflammatory cytokines IL-1β and TNF-α demonstrated a significant decrease following alkali burn. Safety evaluations, including assessments of renal and hepatic biomarkers, along with H&E staining of major organs, revealed no significant cytotoxicity of the MINO@PLGA nanocomplex in vivo.
CONCLUSIONS: The novel MINO@PLGA nanocomplex, comprising minocycline-loaded nHAP/PLGA microspheres, has shown a substantial capacity for preventing CoNV. This study confirms the complex's ability to downregulate inflammatory pathways, significantly reducing CoNV with minimal cytotoxicity and high biosafety in vivo. Given these findings, MINO@PLGA stands as a highly promising candidate for ocular conditions characterized by CoNV.
Eligible patients include women diagnosed with platinum-resistant ovarian cancer or recurrent ovarian cancer cancer. All patient participants will complete two quality of life (QOL) questionnaires and a cost-diary documenting their health care experience at time of consent and every 12 weeks thereafter. Consenting care givers will also be asked to complete two questionnaires to asses the impact of structured palliative care on them every 12 weeks.

Patients will be assigned to two arms randomly: 1) usual care or 2) structured palliative care. The primary endpoint is quality of life. A two-sided Chi-square test will be used to compare the proportion of patients who have improved quality of life after treatment between control arm and intervention arm. The average value of multiple scores after treatment will be used to compare with the baseline score before treatment for each question in the standard questionnaire.
This study is a randomized controlled trial with the aim to investigate if IPDT leads to lowered levels of trait neuroticism. Participants will either be randomized to the treatment which is based on Affect Phobia Therapy or to a wait-list control. Participants will have weekly contact with a therapist who will provide feedback and support.

Primary outcome measure is trait neuroticism (measured on the 24-Item Neuroticism scale of the IPIP-NEO-120). Secondary outcome measures will include measures of anxiety, depression, quality of life, emotion regulation, and defense mechanism adaptiveness. Emotion regulation and short measure of anxiety and depressive symptoms will be collected weekly throughout the treatment period. Pre-treatment measurement, post-treatment measurement, weekly measure, and one-year follow up is planned to be collected through an online survey.
This is individual treatment provided by a trained Cognitive Behavioral Therapy (CBT) clinician who will focus on teaching skills to understand and change participants behaviors to help them avoid alcohol use. Sessions with the clinician will generally last for 1 hour one time per week for 8 weeks. Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
Polynucleotides such as DNA are stored inside vesicles formed from self-assembling membranes. The vesicles may be protocells, liposomes, micelles, colloidosomes, proteinosomes, or coacervates. The vesicles may include surface functionalization to improve polynucleotide encapsulation and/or to bind polynucleotides having specific sequences. Encapsulation in vesicles provides protection for the polynucleotides. Additional protection is provided by addition of one or more stabilizers. The stabilizer may be nucleic-acid stabilizers that stabilize the polynucleotides or may be a protective structural layer around the vesicles such as a layer of silica. A process for stably storing polynucleotides in vesicles and a process for recovering stored polynucleotides from vesicles are both disclosed. The polynucleotides may be used for storage of digital information.
Cardiac amyloidosis (CA) is an infiltrative cardiomyopathy caused by extracellular deposition of amyloid fibrils, mainly derived from transthyretin, either wild-type or hereditary variants, or immunoglobulin light chains misfolding. It is characterized by an increased left ventricular (LV) mass and diastolic dysfunction, which can lead to heart failure with preserved ejection fraction and/or conduction disturbances. The diagnosis is based on invasive pathology demonstration of amyloid deposits, or non-invasive criteria using advanced cardiovascular imaging techniques. Nevertheless, 12-lead electrocardiogram (ECG) remains of crucial importance in the assessment of patients with CA, since they can manifest peculiar features such as low QRS voltages, in discordance with the LV hypertrophy, but also pseudo-infarction patterns, sinus node dysfunction, atrioventricular blocks, premature supraventricular and ventricular beats, which support the presence of a myocardial disease. Great awareness of these common ECG characteristics of CA is needed to increase diagnostic performance and improve patient's outcome. In the present review, we discuss the current role of the ECG in the diagnosis and management of CA, focusing on the most common ECG abnormalities and rhythm disorders.
Tetramethylpyrazine (TMP) belongs to the active ingredients of the traditional Chinese medicine Chuanxiong, which has a certain protective effect in myocardial ischemia-reperfusion (I/R) injury. It can improve postoperative cardiac function and alleviate ventricular remodeling in acute myocardial infarction patients. However, its specific protective mechanism is still unclear. In this study, a certain concentration of TMP was introduced into I/R mice or H9C2 cells after oxygen-glucose deprivation/reoxygenation (OGD/R) treatment to observe the effects of TMP on cardiomyocyte activity, cytotoxicity, apoptosis, autophagy, pyroptosis, and NLRP3 inflammasome activation. The results displayed that TMP intervention could reduce OGD/R and I/R-induced cardiomyocyte apoptosis, accelerate cellular activity and autophagy levels, and ameliorate myocardial tissue necrosis in I/R mice in a dose-dependent manner. Further, TMP prevented the formation of NLRP3 inflammasomes to suppress pyroptosis by increasing the level of cardiomyocyte autophagy after I/R and OGD/R modelling, the introduction of chloroquine to suppress autophagic activity in vivo and in vitro was further analyzed to confirm whether TMP inhibits NLRP3 inflammasome activation and pyroptosis by increasing autophagy, and we found the inhibitory effect of TMP on NLRP3 inflammasomes and its protective effect against myocardial injury were blocked when autophagy was inhibited with chloroquine. In conclusion, this experiment demonstrated that TMP unusually attenuated I/R injury in mice, and this protective effect was achieved by inhibiting the activation of NLRP3 inflammasomes through enhancing autophagic activity.
The invention discloses Chinese compound formula rheumatalgia-relieving plaster emplastrum. Raw materials of the emplastrum include extraction decoction pieces and decoction pieces directly used as medicines. By weight, the extraction decoction pieces including chaff flower root, angelica root, prepared radix rehmanniae, knoxia root, red flower, three-nerved spicebush root, radix rehmanniae, pepper stem, Chinese angelica, radix clematidis, pangolin, unprocessed radix aconite, ephedra, radix angelicae tuhuo, notopterygium root, sappan wood, peach seeds, galangal, teasel root, gastrodia elata, snake slough, common peony root, unprocessed radix aconiti kusnezoffii, cortex acanthopanacis, centipede and asarum are cleaned, coarsely crushed and extracted in a reflux manner, and reflux extracting solution is concentrated to obtain liquid extract. By weight, cinnamon, dragon's blood, frankincense, myrrh, clove, sandalwood, realgar, musk and borneol are crushed to obtain mixed fine powder. Emplastrum matrix and liquid extract are weighed and mixed with the mixed fine powder to obtain coatings, and the coatings are coated on a nonwoven fabric or a blended fabric to obtain the compound formula rheumatalgia-relieving plaster emplastrum. The compound formula rheumatalgia-relieving plaster emplastrum is high in effective component proportion, purity and pharmaceutical effect, fine in stability and safety and low in toxic and side effect, and the release rate of medicines in the emplastrum is increased.
This project is a case control study that is designed to determine prevalence of inherited polymorphic and somatically acquired variants of key TGF-ß pathway components in a large cohort of Appalachian invasive cervical cancer (ICC) patients compared to healthy Appalachian women. It will be determined whether these genetic alterations contribute individually or in combination with other known environmental (Human Papillomavirus, Epstein-Barr Virus), behavioral (smoking), and social (stress, social networks) risk factors, to the increased susceptibility of Appalachian women to ICC development. Women will be recruited from several clinics and physician practices in West Virginia, Charleston and Appalachia Ohio and Kentucky. Participants will be women residing in these area who are 18 years and older, not pregnant, speak English, not cognitively impaired and able to provide informed consent. There will be three distinct types of women recruited into the study; 1. ARM 1 - previously treated for invasive cervical cancer; 2. ARM 2 - newly diagnosed with invasive cervical cancer; and 3. healthy controls - without a diagnosis of cervical cancer.
Implants for repairing tissue defects, such as cartilage tissue defects, and methods of their preparation and use are disclosed. A mold of a tissue defect is prepared by pressing upon the defect a substrate having shape memory, such as aluminum foil. The mold, which has contours substantially conforming to those of the defect, is removed from the defect, and tissue particles are added to the mold ex vivo. A biological carrier such as biocompatible glue is also added to the mold. The combination of tissue particles and the biological carrier thereby form an implant, which retains its shape after separation from the mold. The implant can be transferred to the tissue defect, with contours of the mold matching corresponding contours of the defect.
Patients with a detectable index lesion on mpMRI, PSA level \<20 ng/mL and wishing to undergo a prostatectomy due to significant PCa on biopsy are elibible for this study approved by the Ethics Committee. Targeted biopsies of the index lesion are performed by using an ultrasound-MRI image fusion system with Organ based Tracking (OBT)-registration (Trinity\*, KOELIS, France) to provide quality control. Targeted cores are analyzed intraoperatively with an extemporaneoux analyses. If positive, a targeted focal microwave ablation is achieved during the same session by a single 18G needle inserted transrectally Under sedation. Predictive ablation charts obtained with the 2.45 GHZ frequency microwave generator (TATO, Biomedical Srl, Italy) through ex vivo experiments were used to choose the duration and power of the treatment.

Treated patients are followed-up for 4 to 6 weeks and the planned radical prostatectomy is performed. All treated patients complete uroflowmetry test and questionnaires (IPSS, IPSS-QQL, IIEF-5, and MSHW-EJD-SF) befor, at 7 days and 1 month after the procedure. A mpMRI of the treated prostate is performed at 7 days after the ablation to identify the devascularized area, but also to verify that no organ at risk is affected by the microweve treatment. After radical prostatectomy, whole-mount histology serves to define the ablation boundaries and dimension in the prostate. It also allows to determine the impact of the use of microwaves on cancerous tissue. A total of 10 patients will be enrolled.
Patients with squamous histology will receive pemetrexed and either carboplatin or cisplatin for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion. The choice of platinum-based chemotherapy is also at the investigator's discretion. Patients with non-squamous histology are not eligible for this arm.
PURPOSE: To realize a large scale and economical separation through chromatography by employing glass fibers coated with agarose as a column filler for separating a biological sample or a chromatography member. CONSTITUTION: In order to remove endotoxin in the process of chromatography, a calibrator, e.g. polymyxin B, is immobilized onto agarose coated glass fibers. A substance mixed with endotoxin is then passed on the agarose coated glass fibers modified with a calibrator. Consequently, the endotoxin is adsorbed to the agarose coated glass fibers and removed from the substance. The agarose coated glass fibers can be dispersed easily and exhibits excellent fluidity. Furthermore, low filling density attainable by glass fibers realizes chromatographic processing with high extrusion quantity. Excellent mechanical characteristics of fiber also contribute to the fluid characteristics. This arrangement realizes a large scale economic chromatographic separation.
A compound can be a fluorescent taxane derivative having a structure of Formula 1, salt, stereoisomer, tautomer, polymorph, or solvate thereof. Formula 1 can be defined as: L, L-NH, or L-NH—C═O is a linker; and R is a substituent, where —OH, —O − , —NH 2 , and NH—CH 3  are examples. Examples of linkers can include glycine, beta-alanine, gamma-aminobutyric acid (GABA). Pharmaceutical compositions can include the compound and a pharmaceutically acceptable carrier, and may be configured for intravenous injection. The fluorescent taxane derivative can be used to treat cancer and non-cancer diseases. The fluorescent taxane derivative can be used to monitor cellular efflux and determine whether a cell will efflux paclitaxel.
100 patients undergoing bimaxillary osteotomy under general anesthesia will be included into this prospective cohort study.

There will be two episodes of controlled hypotension for upper and lower jaw respectively. Hypotension will be induced and sustained according to the same procedure as described here. Controlled hypotension will be induced (intravenous administration of nitroglycerin 2-10 µg/kg/min) 15 minutes prior to the start of mucosal detachment, and will be sustained for the osteotomy stage. The surgeon will evaluate the surgical field quality (in terms of bleeding) according to Modena Bleeding Score (MBS), with scores 1-2 being satisfactory to proceed with the osteotomy. The following arterial pressure correction (proceeding with controlled hypotension or returning to normotension) will depend on the bleeding in the surgical field and the monitoring of cerebral oxygen saturation carried out using near-infrared spectroscopy (NIRS) . The lowest targeted arterial pressure in order to have a clear surgical field will be 55 mmHg. However when the cerebral oxygen saturation decreases by 20% compared with the baseline at any arterial pressure level intervention would be carried out by Norepinephrine (intravenous, individual dosage for each patient - as judged by the anesthesiologist). Arterial blood samples will be taken at 3 time points (at the start of the surgery, during controlled hypotension phase, after extubation) for arterial gas analysis. Two blood samples will be taken to measure (prior to surgery and immediately after surgery) neuron-specific enolase (NSE), cystatin c and troponin I levels. The general condition, operation, anesthesia and hospitalization related data of the patients will be recorded. Cognitive function will be evaluated within 3 days before surgery and 2 days and 1 month after surgery.
To provide a seal creation device with which an affected part of a person can be quantitatively observed.SOLUTION: A seal creation device 100 comprises: a reading unit 110; a specification unit 120; and a creation unit 130. The reading unit 110 reads a figure 6 showing the position of an affected part 2 and at least two marks 8 specifying the position of affected part 2 on the body from a medium 10 including the figure 6 and marks 8. The specification unit 120 acquires information specifying the figure 6 and marks 8 read by the reading unit 110. The creation unit 130 creates a document image 200 formed on an affected part observation seal 300 for observing the affected part 2 on the basis of the information from the specification unit 120. The document image 200 includes a window image 206, a first comparison image 211, and at least two mark images 208. The window image 206 shows an image corresponding to a window for observing the affected part 2. The first comparison image 211 shows an image to be compared with the affected part 2. The mark images 208 show images corresponding to the marks 8.SELECTED DRAWING: Figure 1
The invention discloses a capsule for treating hypertension. The capsule is characterized in that the capsule is prepared from the following traditional Chinese medicinal raw materials, by weight, 2 parts of radix astragali, 20 parts of red sage root, 6 parts of root of kudzu vine, 8 parts of Chinese yam, 10 parts of ginkgo biloba, 16 parts of corn silk, 16 parts of gynostemma pentaphylla, 7 parts of pseudo-ginseng, 35 parts of haw, 3 parts of perilla, 2 parts of apocynum venetum, 5 parts of wild chrysanthemum flower, 2 parts of prunella vulgaris, 17 parts of uncaria, 16 parts of wolfberry, 3 parts of concha haliotidis, 6 parts of eucommia, 10 parts of raw oyster shell, 15 parts of white peony root, 15 parts of achyranthes root, 3 parts of lotus plumule, 10 parts of Poria cocos, 10 parts of rhizoma alismatis and 10 parts of rhizoma gastrodiae. Symptoms of a patient can be alleviated within a short period of time after the capsule is taken. The capsule has effects of reducing blood pressure and blood lipid. Curative effect is stable; drug effect is definite; and the technology is feasible. The capsule has little side effect if a patient takes the capsule for a long time. After drug discontinuance, hypertension is not easy to recur. Costof the capsule is low.
BACKGROUND: It is not fully established whether plasma β-amyloid(Aβ)42/Aβ40 and phosphorylated Tau181 (p-Tau181) can effectively detect Alzheimer's disease (AD) pathophysiology in older Chinese adults and how these biomarkers correlate with astrocyte reactivity, Aβ plaque deposition, tau tangle aggregation, and neurodegeneration.
METHODS: We recruited 470 older adults and analyzed plasma Aβ42/Aβ40, p-Tau181, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) using the Simoa platform. Among them, 301, 195, and 70 underwent magnetic resonance imaging, Aβ and tau positron emission tomography imaging. The plasma Aβ42/Aβ40 and p-Tau181 thresholds were defined as ≤0.0609 and ≥2.418 based on the receiver operating characteristic curve analysis using the Youden index by comparing Aβ-PET negative cognitively unimpaired individuals and Aβ-PET positive cognitively impaired patients. To evaluate the feasibility of using plasma Aβ42/Aβ40 (A) and p-Tau181 (T) to detect AD and understand how astrocyte reactivity affects this process, we compared plasma GFAP, Aβ plaque, tau tangle, plasma NfL, hippocampal volume, and temporal-metaROI cortical thickness between different plasma A/T profiles and explored their relations with each other using general linear models, including age, sex, APOE-ε4, and diagnosis as covariates.
RESULTS: Plasma A+/T + individuals showed the highest levels of astrocyte reactivity, Aβ plaque, tau tangle, and axonal degeneration, and the lowest hippocampal volume and temporal-metaROI cortical thickness. Lower plasma Aβ42/Aβ40 and higher plasma p-Tau181 were independently and synergistically correlated with higher plasma GFAP and Aβ plaque. Elevated plasma p-Tau181 and GFAP concentrations were directly and interactively associated with more tau tangle formation. Regarding neurodegeneration, higher plasma p-Tau181 and GFAP concentrations strongly correlated with more axonal degeneration, as measured by plasma NfL, and lower plasma Aβ42/Aβ40 and higher plasma p-Tau181 were related to greater hippocampal atrophy. Higher plasma GFAP levels were associated with thinner cortical thickness and significantly interacted with lower plasma Aβ42/Aβ40 and higher plasma p-Tau181 in predicting more temporal-metaROI cortical thinning. Voxel-wise imaging analysis confirmed these findings.
DISCUSSION: This study provides a valuable reference for using plasma biomarkers to detect AD in the Chinese community population and offers novel insights into how astrocyte reactivity contributes to AD progression, highlighting the importance of targeting reactive astrogliosis to prevent AD.
Cosmetic complex has an emulsifying value which is (approx.) equal to emulsifying value (HLBr) of sebaceous matter film at the human body positions to which the cosmetic is to be applied. For face-treatment cosmetics, HLBr is esp. 10.4-10.7, whereas for hair cosmetics it is 12.4-12.8. HLBr control prevents sebaceous matter film decompsn. by cosmetics and scalp disorders caused by soaps and shampoos. The sebaceous matter film can be compensated for and replenished.
Systems and methods perform signature extraction from an acquired spectrum of a pharmaceutical. An acquired spectrum of the pharmaceutical is measured using a spectrometer. The acquired spectrum is obtained from the spectrometer using a processor. A system-response function of the spectrometer is removed from the acquired spectrum using the processor. An intensity of the acquired spectrum is normalized to a predetermined scale using the processor. Fluorescence is removed from the acquired spectrum using the processor. Finally, an extracted signature of the pharmaceutical is obtained from the remainder of the acquired spectrum using the processor. If the acquired spectrum of the pharmaceutical is measured by the spectrometer through a container holding the pharmaceutical, a spectrum of the container is removed from the remainder of the acquired spectrum to produce the extracted signature of the pharmaceutical using the processor.